Battling Neuropathic Scar Pain With Botulinum Toxin
Abstract
Botulinum toxin type A (BTA) is a neurotoxic protein that prevents the release of neurotransmitters from presynaptic nerves and has shown promise in treating neuropathic pain. Recently, BTA has been used to treat painful keloids and scars. We present a patient with refractory neuropathic pain in a normotrophic spread-scar treated with the injection of BTA.
A 47-year-old Caucasian female …
Abstract
Botulinum toxin type A (BTA) is a neurotoxic protein that prevents the release of neurotransmitters from presynaptic nerves and has shown promise in treating neuropathic pain. Recently, BTA has been used to treat painful keloids and scars. We present a patient with refractory neuropathic pain in a normotrophic spread-scar treated with the injection of BTA.
A 47-year-old Caucasian female … Continue reading "Battling Neuropathic Scar Pain With Botulinum Toxin"
Podcast host Dr. Adam Friedman sat down with Dr. Shari Lipner, associate professor of dermatology at New York-Presbyterian Hospital/Weill Cornell Medical Center and international nail expert extraordinaire, to discuss the accuracy and quality of internet based information on Onychomycosis.
Dr. Aaron Fong, PGY-3 dermatology resident at George Washington University School of Medicine and Health … 
Authors Jacob Reinhart MD, Matthew Willett MD, and Neil Gibbs MD present a case of psoriatic lesions precipitated by an upper arm tattoo.
Psoriasis is a common dermatologic skin condition with a variety of morphologic presentations. These variations include the less common hyperkeratotic form, psoriasis ostracea, defined as having pronounced adherent scales (skin lesions) resembling an oyster s … 
Here are the issue highlights for the JDD August issue with special focus on Psoriasis:
Authors discuss the epidemiological, clinical, and histologic features of melasma and postinflammatory hyperpigmentation and important considerations for both established and emerging treatments in Therapeutic Insights in Melasma and Hyperpigmentation Management (CE credit is available)
Descriptive char … 
A 67-year-old African American male recently diagnosed with metastatic renal cell carcinoma presents to clinic for evaluation of pruritic and burning skin findings (see clinical images below) that developed two weeks after he started treatment with bevacizumab and erlotinib. Which of the following medications would not cause this eruption?
A. Cetuximab
B. Erlotinib
C. Panitumumab
D … 